NoGeneST™ Anti-C5 Aptamer, aC5 aptamer-2 sodium

Name: NoGeneST™ Anti-C5 Aptamer, aC5 aptamer-2 sodium
SKU: NRYF-0625-HZ63
Rating: 5 (1 reviews)

[CAT#: NRYF-0625-HZ63]

An amine-modified RNA aptamer that inhibits Complement C5, functionalized for covalent conjugation to other molecules.

Target:: C5

Type:: RNA

Datasheet MSDS Request COA

Certificate of Analysis Lookup
To download a Certificate of Analysis, please enter a lot number in the search box below. Note: Certificate of Analysis not available for kit components.
Lot Number

Inquiry

Product Overview

Description

This is an RNA aptamer that specifically binds to human Complement C5, blocking its convertase-catalyzed activation and thus inhibiting the terminal complement pathway. The aptamer is supplied with a terminal 6-carbon primary amine (NH2-C6) linker, which provides a reactive site for stable covalent coupling to other molecules, such as fluorophores, biotin, or drug payloads, making it a versatile tool for assay development and targeted applications.

Type

RNA

Properties

Size

1 mg; 5 mg; 10 mg

Appearance

Supplied as a lyophilized white to off-white solid.

Purity

>90%

Shipping

Room temperature

Storage

Powder Form: Stable for 3 years when stored at -20°C.
In Solvent: Stable for 6 months when aliquoted and stored at -80°C

Research Use Only

For Research Use Only

Target Details

Target

Full Name

Complement component 5

Gene ID

727

Uniprot ID

P01031

Target Overview

Complement component 5 (C5) is the central protein that initiates the terminal, lytic pathway of the complement system. During complement activation, it is cleaved by C5 convertase into two potent, biologically active fragments: C5a and C5b. The C5a fragment is a powerful anaphylatoxin that mediates inflammation by recruiting and activating immune cells. The C5b fragment initiates the assembly of the C5b-9 complex, also known as the Membrane Attack Complex (MAC), which creates pores in cell membranes, leading to cell lysis. This dual role in driving both inflammation and direct cell destruction makes C5 a critical therapeutic target.

Publications